Navigation Links
CeQur SA Appoints Eric Milledge Chairman of the Board of Directors

MONTREUX, Switzerland, Oct. 6 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of insulin delivery systems to improve the management of type 2 diabetes, announced the appointment of Eric Milledge as chairman of the company's board of directors, effective immediately.

Milledge is a 34-year veteran of Johnson and Johnson Corporation, where he most recently served as company group chairman of Lifescan Inc., the market leader in blood glucose monitoring. During his tenure, Milledge led the acquisition of Animas Corporation, which enabled J&J to become a major force in the insulin pump arena. He also led the acquisition of Inverness Medical, a pivotal $1.3 billion deal in the glucose monitoring space.

Previous to being named group chairman of J&J Healthcare Systems and Lifescan Inc., Milledge had served as president of Ortho Pharmaceuticals, president of Ortho-McNeil Pharmaceuticals, and as a board member of the Johnson and Johnson Development Corporation, the company's internal venture arm. Milledge retired from Johnson and Johnson in March 2006.

"Eric brings to CeQur a demonstrated ability to lead the successful development and commercialization of medical devices that improve quality of life for people with diabetes," said Jim Peterson, vice-chairman and CEO, CeQur. "We are extremely pleased to have the benefit of his vast experience to help guide our company."

CeQur is developing the CeQur(TM) Insulin Infuser, a discreet, wearable device that provides three days of consistent, basal insulin delivery along with on-demand bolus insulin at the push of a button. The small device comprises a disposable infuser reservoir attached to a reusable electronic monitor.

"The CeQur Insulin Infuser is a simple alternative that will offer people with type 2 diabetes freedom from multiple, daily insulin injections," said Milledge. "As people living with the disease know, maintaining glycemic control and managing multiple, daily insulin injections is a continuous challenge. I'm pleased to be part of CeQur's mission to make it easier for people with type 2 diabetes to stay in control of their disease."

About CeQur SA

CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.

CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company's lead product candidate is the CeQur(TM) Insulin Infuser, a novel, wearable insulin delivery device that provides freedom from multiple daily injections by offering up to three days of consistent, basal insulin delivery along with bolus insulin at the push of a button. More information can be found at


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Appoints New Chief Medical Officer
2. West Pharmaceutical Services, Inc. Appoints New Director
3. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
4. Curemark Appoints Preeminent Pediatrics Gastroenterologist
5. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. NovaRx Appoints Industry Veteran as President and COO
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Post Your Comments:
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... ... 27, 2015 , ... The print component of “Supporting Our ... Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies ... a vast social media strategy and across a network of top news sites ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
Breaking Medicine News(10 mins):